Abstract: Aspects of the application provide methods and compositions for identifying and evaluating putative therapeutic agents for cancer by live cell imaging. Cell samples comprising cancerous cells that have been pre-treated with a test agent are contacted with a BH3 peptide, and samples are imaged by live cell imaging over a time interval. Methods of the application can be used to determine whether a patient is likely to benefit from treatment with a particular test agent.

Abstract: A compound, which is according to formula I or is a pharmaceutically acceptable salt, solvate, ester or pro-drug thereof, for use as a medicament, wherein either (i) NR1R2 together forms a 5- or 6-membered heterocyclic ring or (ii) R1 and R2 are independently selected from H and C1 to C12 alkyl; A is a non-aromatic ring, an aromatic ring or a double bond; X is NR3, S or O, where R3 is selected from H and C1 to C12 alkyl; Y is S, NR4, CR4R5, or O, where R4 and R5 are independently selected from H and C1 to C12 alkyl; and Z is (CR6R7)n where R6 and R7 are independently selected from H and C1 to C12 alkyl and n is an integer from 1 to 6. The compounds of formula I are particularly useful for the treatment of cancer, neurodegenerative diseases and/or inflammation.

Abstract: As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.

Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.

Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.

Abstract: The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.

Abstract: Aspects of the application provide methods and compositions for identifying and evaluating putative therapeutic agents for cancer by live cell imaging. Cell samples comprising cancerous cells that have been pre-treated with a test agent are contacted with a BH3 peptide, and samples are imaged by live cell imaging over a time interval. Methods of the application can be used to determine whether a patient is likely to benefit from treatment with a particular test agent.

Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.

Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.

Abstract: The present invention provides methods of assessing toxicity using Dynamic BH3 profiling.

Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.

Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.

Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.

Abstract: In various aspects the invention provides methods of predicting sensitivity of a cancer cell to a therapeutic agent by contacting a test cell population BH3 domain peptide; measuring the amount of BH3 domain peptide induced mitochondrial outer membrane permeabilization in the test cell population; and comparing the amount of BH3 domain peptide induced mitochondrial outer membrane permeabilization in the test cell population to a control cell population that has not been contacted with the therapeutic agent. An increase in mitochondrial membrane permeabilization in the test cell population compared to the control cell population indicates the cell is sensitive to the therapeutic agent.

Abstract: The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.

Abstract: The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.

Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.

Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.

Abstract: The present invention provides methods of assessing toxicity using Dynamic BH3 profiling.

Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.